The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | The CLL Treatment Infection Model: identifying patients with CLL at high risk of infections
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the use and validation of a machine learning-based chronic lymphocytic leukemia Treatment Infection Model (CLL-TIM) to identify newly diagnosed patients at a high risk of developing serious infections or requiring early treatment in the PreVent-ACaLL trial (NCT03868722). Dr Niemann discusses the performance of the CLL-TIM model and explains that it can successfully identify patients at a high or low risk of infection. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding and/or consultancy fees from Abbvie, Janssen, AstraZeneca, Beigene, Octapharma, Genmab, Takeda, CSL Behring, Eli Lilly
